Numerous investigations on the tumour-suppressing activity of Cygb have been reported since 2005; the studies showed that most cancer cells and tissues have reduced expression of Cygb and/or loss of heterozygosity, in addition to promoter hypermethylation both in vitro and in vivo14, 18, 19, 62. The gene discussed is CYGB; the disease is neoplasm.